We are live on
!
Find out more
NCM
Nantahala Capital Management Portfolio holdings
AUM
$2.72B
1-Year Est. Return
121.58%
This Fund
S&P 500
This Quarter
Est. Return
+11.08%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.03B
AUM Growth
-$271M
(-21%)
Cap. Flow
-$280M
Cap. Flow
% of AUM
-27.07%
Top 10 Holdings %
Top 10 Hldgs %
51.2%
Holding
145
New
21
Increased
20
Reduced
48
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Bancorp
TBBK
|
+$12.6M |
| 2 |
Cytokinetics
CYTK
|
+$5.52M |
| 3 |
Dyne Therapeutics
DYN
|
+$4.89M |
| 4 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$4.82M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$4.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TA
TravelCenters of America LLC
TA
|
+$51.7M |
| 2 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$45.4M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$24M |
| 4 |
Travel + Leisure Co
TNL
|
+$23.3M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$13.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.04% |
| 2 | Financials | 9.2% |
| 3 | Consumer Discretionary | 9.01% |
| 4 | Communication Services | 6.73% |
| 5 | Industrials | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Aura Biosciences
AURA
$826M
| $9.92M | 0.96% |
803,325
-40,121
| -5% | -$429K |
|
27
DarioHealth
DRIO
$71.2M
| $9.7M | 0.94% |
120,925
| – | – |
|
|
28
CALL
iShares Russell 2000 ETF
IWM
$81.9B
| $9.36M | 0.91% |
+50,000
| New | +$8.91M |
|
29
MillerKnoll
MLKN
$1.67B
| $8.98M | 0.87% |
607,883
-326,150
| -35% | -$5.21M |
|
30
PUT
Blackstone Mortgage Trust
BXMT
$2.38B
| $8.32M | 0.81% |
+400,000
| New | +$7.35M |
|
31
CALL
Herbalife
HLF
$1.29B
| $7.94M | 0.77% |
600,000
| – | – |
|
32
DXP Enterprises
DXPE
$2.98B
| $7.78M | 0.75% |
213,672
-124,418
| -37% | -$3.76M |
|
|
ILPT
33
Industrial Logistics Properties Trust
ILPT
$586M
| $7.78M | 0.75% |
2,357,284
+1,097,000
| +87% | +$2.45M |
|
34
Payoneer
PAYO
$2.41B
| $7.76M | 0.75% |
1,612,862
+102,247
| +7% | +$511K |
|
35
Reading International Class A
RDI
$34.3M
| $7.65M | 0.74% |
2,885,514
-10,181
| -0.4% | -$30.4K |
|
36
Alta Equipment Group
ALTG
$245M
| $7.33M | 0.71% |
422,812
-204,295
| -33% | -$3.02M |
|
37
CALL
Zoom
ZM
$30.6B
| $6.79M | 0.66% |
100,000
| – | – |
|
|
38
Syndax Pharmaceuticals
SNDX
$1.82B
| $6.76M | 0.65% |
323,134
-652,571
| -67% | -$13.6M |
|
|
39
Dyne Therapeutics
DYN
$4.9B
| $6.67M | 0.65% |
593,164
+414,263
| +232% | +$4.89M |
|
40
Amneal Pharmaceuticals
AMRX
$5.79B
| $6.66M | 0.64% |
2,149,305
+1,649,305
| +330% | +$3.51M |
|
|
KRTX
41
CALL
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.51M | 0.63% |
+30,000
| New | +$6.43M |
|
42
eHealth
EHTH
$43.9M
| $6.43M | 0.62% |
800,000
+400,000
| +100% | +$3.2M |
|
|
VTYX
43
DELISTED
Ventyx Biosciences
VTYX
| $6.32M | 0.61% |
192,671
| – | – |
|
|
RDNW
44
CALL
RideNow Group
RDNW
$262M
| $6.18M | 0.6% |
+500,000
| New | +$4.67M |
|
|
CBAY
45
DELISTED
Cymabay Therapeutics
CBAY
| $6.06M | 0.59% |
553,307
-1,236,796
| -69% | -$11.5M |
|
46
CALL
Peloton Interactive
PTON
$2.49B
| $6M | 0.58% |
780,000
| – | – |
|
|
47
Cytokinetics
CYTK
$10.4B
| $5.85M | 0.57% |
179,257
+149,257
| +498% | +$5.52M |
|
48
Abeona Therapeutics
ABEO
$413M
| $5.65M | 0.55% |
1,401,880
-26,795
| -2% | -$93.7K |
|
|
PNT
49
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $5.18M | 0.5% |
572,191
| – | – |
|
50
InspireMD
NSPR
$34.7M
| $4.67M | 0.45% |
+1,860,405
| New | +$2.96M |
|
Similar funds
TAM
XL
NB
PA
BCM
SCM
HCM
GC
Nantahala Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Nantahala Capital Management held 145 positions worth $1.03B, down 21% from $1.31B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Nantahala Capital Management withdrew a net $280M in Q2 2023, closing 21 positions and reducing 48 holdings. Its most notable exit was TravelCenters of America LLC, an estimated $51.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 38% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Nantahala Capital Management opened a new position in The Bancorp worth $13.3M.
- Nantahala Capital Management's largest Q2 2023 buy was The Bancorp: 407,946 shares worth $13.3M.
- Nantahala Capital Management added most to Cytokinetics in Q2 2023, an estimated $5.52M increase.
- Nantahala Capital Management's biggest Q2 2023 reduction was iShares Russell 2000 ETF, cutting an estimated $24M.
- Nantahala Capital Management fully exited TravelCenters of America LLC in Q2 2023, selling an estimated $51.7M.
- Nantahala Capital Management's ten largest holdings make up 51% of its $1.03B portfolio in Q2 2023.
- Nantahala Capital Management opened 21 new positions and closed 21 in Q2 2023.
- Nantahala Capital Management's portfolio value fell 21% quarter-over-quarter to $1.03B.
Based on Nantahala Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.